Insulin Lispro

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Type1 Diabetes Mellitus

Conditions

Type1 Diabetes Mellitus

Trial Timeline

Nov 8, 2017 → Feb 9, 2018

NCT ID

NCT03367390

About Insulin Lispro

Insulin Lispro is a phase 1 stage product being developed by Eli Lilly for Type1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT03367390. Target conditions include Type1 Diabetes Mellitus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05893797	Pre-clinical	Completed	Oct 5, 2023	Sep 16, 2024	Type 1 Diabetes
NCT03890003	Pre-clinical	Completed	Mar 28, 2019	May 6, 2019	Type 1 Diabetes Mellitus
NCT03849612	Pre-clinical	Completed	Feb 21, 2019	Mar 27, 2019	Type 1 Diabetes Mellitus
NCT03848767	Pre-clinical	Completed	Feb 20, 2019	Apr 1, 2019	Type 1 Diabetes Mellitus
NCT03743285	Pre-clinical	Completed	Nov 14, 2018	Jan 28, 2019	Type 1 Diabetes Mellitus
NCT02623452	Phase 1	Withdrawn	Jan 1, 2018	Apr 1, 2018	Diabetes Mellitus, Type 1
NCT02623478	Phase 1	Withdrawn	Jan 1, 2018	Apr 1, 2018	Diabetes Mellitus, Type 1
NCT02623465	Phase 1	Withdrawn	Jan 1, 2018	Apr 1, 2018	Diabetes Mellitus, Type 2
NCT03368807	Pre-clinical	Completed	Dec 11, 2017	Jul 23, 2018	Diabetes Mellitus, Type 1
NCT03367390	Phase 1	Completed	Nov 8, 2017	Feb 9, 2018	Type1 Diabetes Mellitus
NCT02111083	Phase 1	Completed	May 1, 2014	Aug 1, 2014	Healthy Volunteers

Competing Products

11 competing products in Type1 Diabetes Mellitus

See all competitors

Product	Company	Stage	Hype Score
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose	Precigen	Phase 1/2	36
LY900014 + Insulin Lispro	Eli Lilly	Phase 2	52
Selumetinib	AstraZeneca	Pre-clinical	23
Dapagliflozin + Placebo Oral Tablet	AstraZeneca	Phase 1	33
Semaglutide Pen Injector + Placebo	Novo Nordisk	Phase 2	51
Aspart	Novo Nordisk	Approved	84
Insulin glargine new formulation HOE901	Sanofi	Phase 1	32
Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin	Sanofi	Phase 1	32
verapamil 120mg tablet + placebo	Dexcom	Phase 3	74
UP421	Sana Biotechnology	Phase 1	28
XeriSol glucagon	Xeris Pharmaceuticals	Phase 1	28

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved